Topical calcipotriol in the treatment of chronic plaque psoriasis in Bangladeshi skin
Keywords:
Calcipotriol (DAIVONEX), psoriasis treatment, PASIAbstract
Background Calcipotriol (DAIVONEX) ointment has been shown to be effective in thetreatment of chronic plaque psoriasis.Objective To assess the efficacy and safety of calcipotriol ointment (50μg/g) in the treatmentof chronic plaque psoriasis.Patients and methods A total of 61 patients (39 males, 22 females, age range from 18 to 76years) of chronic plaque psoriasis were enrolled in an open prospective trial. 51 completedthe study. Calcipotriol ointment was applied twice daily for up to 6 weeks on lesional area,following a 2 weeks washout phase with liquid paraffin. Efficacy, as measured by thePsoriasis Area and Severity Index (PASI), and safety were assessed at 2, 4 and 6 weeks.Results Reduction of PASI was statistically highly significant at all visits. The mean PASIfell in 6 weeks from 10.47 to 2.18 (P<0.001). Analysis of patient assessment at 6 weeksshowed total clearance in 8% of patients and marked improvement in 71% of patients. Theserum calcium level remained unchanged.Conclusion Topical application of 50μg/g calcipotriol ointment was found to be effective andsafe in the treatment of chronic plaque psoriasis.References
Binderup L, Bramm E. effects of
a novel vitamin D analogue MC
on cell proliferation and
differentiation in vitro and on
calcium metabolism in vivo.
Biochem Pharmacol 1988; 37:
-95.
Kragballe K. MC 903. a noncalciotropic
vitamin D3 analogue
stimulates differentiation and
inhibits proliferation of cultured
human keratinocytes. J invest
Dermatol 1988; 91: 383 (Abstr).
Kragballe K, Beek HI, Segaard
H. Improvement of psoriasis by a
topical vitamin D3 analogue (MC
in a double blind study. Br J
Dermatol 1988; 119: 223-30.
Kragballe K. Treatment of
psoriasis by the topical
application of novel vitamin D3
analogue (MC 903). Arch
Dermatol 1989; 125: 1647-52.
Kragballe K, Gjertsen BT. De
Hoop D et al. Double-blind,
right/left comparison of
calcipotriol and betamethasone
valerate in treatment of psoriasis
vulgaris. Lancet 1991; 337: 193-
Cunliffe WJ, Berth-Jones J,
Claudy A et al. Comparative
study of calcipotriol (MC 903)
ointment and betamethasone 17-
valerate ointment in patients with
psoriasis vulgaris. J Am Acad
Dermatol 1992; 26: 736-43.
Berth-Jones J, Chu AC, Dodd
WAH et al. A multicentre
parallel group comparison of
calcipotriol ointment and short
contact dithranol therapy in
chronic plaque psoriasis. Br J
Dermatol 1992; 127: 266-71.
Frederiksson T, Petterson U. Oral
therapy with a new retinoid.
.Dermatologica 1978; 157: 238-
Darley CR, Cunliffe WJ, Green
CM et al. Safety and efficacy of
calcipotriol ointment
(DOVONEX) in treating children
with psoriasis vulgaris. Br J
Dermatol 1996; 135: 390-3.
SN Tham, KC Lun, WK Cheong.
A comparative study of
calcipotriol ointment and tar in
chronic plaque psoriasis. Br J
Dermatol 1994; 131: 673-7.
Dwyer C, Chapman RS.
Calcipotriol and hypercalcemia.
Lancet 1991, 338: 764-5.
Dubertrat L, Wallach D.
Souteyrand P et al. Efficacy and
safety of calcipotriol (MC 903)
ointment in psoriasis vulgaris. J
Am Acad Dermatol 1992; 27:
-8.
Klaber MR, Hutchinson PE,
Holden C et al. Long term
treatment of psoriasis with
calcipotriol. Br J Dermatol 1992;
(Suppl. 40):17 (abstract).
